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Fibrinogen and Bleeding in Cardiac Surgery: 
Clinical Studies in Coronary Artery Bypass Patients 
 
Martin Karlsson 
Department of Cardiovascular Surgery and Anesthesia, Sahlgrenska University Hospital 
and University of Gothenburg  
 
Background: Cardiac surgery is accompanied by inflammatory activation and bleeding 
complications. Fibrinogen is a key factor in the coagulation cascade and can be used to treat 
ongoing bleeding, but is not well studied as prophylactic treatment to prevent bleeding in 
patients with normal plasma fibrinogen levels or as a predictive tool to identify patients with 
increased bleeding risk. 
Aims: To investigate the association between biomarkers of inflammation and hemostasis 
after off pump coronary artery bypass grafting (OPCAB). Further, to study the relationship 
between plasma fibrinogen concentration and postoperative bleeding and transfusion after on 
pump coronary artery bypass grafting (CABG). To investigate if prophylactic fibrinogen 
infusion reduces bleeding and transfusions after CABG. Finally, to study the effect of 
fibrinogen infusion on markers of coagulation, fibrinolysis and platelet function. 
Materials and methods: In study I, biomarkers of inflammation (Il-6, Il-8, PMN-elastase, 
C3a, sC5b-9) and hemostasis (platelet count, β-thromboglobulin, anti-thrombin, D-dimer and 
fibrinogen) were measured before and after surgery in 10 OPCAB patients. II: plasma 
fibrinogen was analyzed the day before surgery in 170 elective CABG patients and related to 
postoperative bleeding and transfusions. III: 20 patients were randomized to preoperative 
infusion of 2 grams (g) fibrinogen concentrate or placebo. Side effects, bleeding and 
transfusions were registered. IV: Biomarkers of coagulation, fibrinolysis and platelet 
activation in relation to fibrinogen treatment were analyzed in the same patients as in study 
III. 
Results: I: Inflammatory markers did not change during surgery while β-thromboglobulin 
increased and anti-thrombin and fibrinogen decreased. There were significant correlations 
between several markers of inflammation and hemostasis. II: Postoperative bleeding volume 
correlated univariately with preoperative fibrinogen concentration (r = -0.53, p<0.001). 
Fibrinogen was an independent predictor of postoperative bleeding volume and blood 
transfusions. III: Infusion of 2g fibrinogen increased plasma levels by 0.6 ± 0.2 g/l and 
reduced postoperative blood loss by 32%. There were no clinically detectable adverse events 
of fibrinogen infusion. IV: Fibrinogen infusion induced no or minimal changes in most 
investigated biomarkers, except D-dimer which was significantly higher 2h after surgery in 
the fibrinogen group. 
Conclusions: There is evidence for an association between the inflammatory response and 
hemostasis after cardiac surgery. The preoperative fibrinogen concentration is a limiting 
factor for postoperative hemostasis. Preoperative measurement of fibrinogen provides 
information about bleeding volume and transfusion requirements after CABG. Prophylactic 
fibrinogen infusion significantly reduces postoperative bleeding without clinical adverse 
events. Infusion of 2g fibrinogen to cardiac surgery patients results in no or minimal changes 
in biomarkers reflecting coagulation and platelet function. 
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Abbreviations 
 
ACT activated clotting time 
ALAT alanine-aminotransferase 
ANOVA analysis of variance 
AT  antithrombin 
APTT activated partial thromboplastin time 
ASAT aspartate-aminotransferase 
AUC area under the curve 
β  beta 
CABG coronary artery bypass grafting 
CI  confidence interval 
CFT clot formation time 
CPB cardiopulmonary bypass  
CT  computed tomography 
CT  clotting time  
ECC extra-corporeal circulation 
ECG electrocardiogram 
F  female 
FVII factor seven 
Fig.  figure 
g  gram 
g/L  gram per litre 
GP  glycoprotein 
h  hours 
Hb  hemoglobin 
Il  interleukin 
IU  international unit (-s) 
LMWH low molecular weight heparin 
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LVEF left ventricular ejection fraction 
M  male 
mL  milliliter 
MCF maximum clot firmness 
N  number 
ng  nanogram   
NSAID non-steroidal anti-inflammatory drug 
OR  odds ratio 
OPCAB off-pump coronary artery bypass (surgery) 
%  percent 
PE  pulmonary emboli 
PF 1&2 prothrombin fragment 1&2 
pg  picogram 
PLT platelet(s) 
PMN polymorph nuclear (leukocytes) 
PT  prothrombin time    
RBC red blood cells 
SD  standard deviation 
SIRS systemic inflammatory response syndrome 
TAT thrombin-antithrombin complex 
U  unit (-s)  
μg  microgram
Introduction 
1. Introduction 
 
Cardiac surgery as treatment of cardiovascular disease has been routinely performed ever 
since it was introduced in the 1950s 1. The majority of operations are performed with the use 
of cardiopulmonary bypass (CPB) and a heart-lung machine 2, although surgery on the 
beating heart (without heart-lung machine) is sometimes used as an alternative 3, 4. Surgery 
with heart-lung machine is often referred to as <on-pump> while surgery without heart-lung 
machine is referred to as <off-pump>. The heart-lung machine has been constantly evolved 
ever since it was first invented and used in 1953 by John and Mary Gibbon 5. With the 
discovery and commercial production of the anticoagulant heparin, these two inventions 
launched the start of the modern era of cardiovascular surgery, followed by a worldwide 
expansion 6-8. In Sweden, approximately 7300 open heart surgery procedures were performed 
in 2008, with an overall 30 day mortality of 2.5 % (Swedish Heart Surgery Registry, annual 
report 2008). Although constantly evolving, cardiac surgery is still accompanied with a risk of 
severe complications such as bleeding 9, 10, infections 11, 12, stroke 13, 14, myocardial infarction 
with heart failure 15, 16, renal insufficiency 17, 18 and pulmonary dysfunction 19, 20. Some of the 
pathophysiological causes leading to these complications have been associated with the 
profound inflammatory reaction and disturbed hemostasis accompanying cardiac surgery. 
 
 
Cardiac surgery and inflammation 
Cardiac surgery with or without CPB induces a systemic inflammatory response, which may 
contribute to postoperative complications such as bleeding and respiratory failure 21-25. The 
contact of blood with the nonendothelial surfaces of the cardiopulmonary bypass circuit and 
the open wound leads to massive activation of the inflammatory and coagulation systems and 
release of proinflammatory and procoagulant factors. The onset of the inflammatory reaction 
is characterized by complement activation followed by activation of different cell types and 
subsequent release of proinflammatory cytokines, which may lead to tissue injury and organ 
dysfunction (Fig. 1) 22, 24-26. 
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Fig. 1. Cardiac surgery leads to activation of the complement system which activates cells, 
leading ultimately to tissue damage and various degrees of organ dysfunction. The tissue 
damage may result in further cell activation and cytokine release.  
 
 
The complement system consists of plasma proteins and is a part of the human humoral 
immune system against bacterial and viral infections 27. The complement factors may be 
activated by infectious pathogens, but also by trauma such as cardiac surgery and CPB 22, 26. 
Complement factor C3 plays a central role in the complement system 22. The exposure of 
blood to extracorporeal circuits leads to the activation of C3 and a triggered auto-conversion 
in a feedback loop to C3a and C3b 28. While C3a is cleaved off as a split product, C3b cleaves 
C5 to C5a and C5b. C5b interacts with other complement factors (C6, C7, C8 and C9) to form 
the terminal sC5b-9 complement complex, also known as the membrane attack complex 
(MAC) 27. The anaphylatoxins C3a and C5a are complement split products and act as 
mediators of inflammatory reactions. Plasma concentrations of complement split products and 
cytokines, representing the magnitude of the inflammatory reaction, have been related to 
clinical outcome in pediatric and adult cardiac surgery 22, 29, 30. However, the inflammatory 
response is complex and many different factors contribute. The surgical trauma itself is a 
contributing factor to the inflammatory reaction and complement activation, also in patients 
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operated without CPB 31. Ischemia and reperfusion injury of vital organs and endotoxin 
release may also contribute 32-34.  
 
 
Cardiac surgery and bleeding 
Bleeding is another common and severe complication after cardiac surgery 35. When surgery 
is completed, the patient is equipped with chest tubes to drain the thoracic cavity from blood 
and fluid. In normal cases, postoperative mediastinal drainage averages about 900 milliliter 
(range 400 – 2200 milliliter) 36. However, approximately 3-7 % of the patients must undergo 
an urgent re-exploration because of extensive bleeding from the chest tube drainage, 
sometimes with concomitant circulatory instability 10, 37-39 Bleeding is therefore a serious 
complication after cardiac surgery and may result in increased morbidity and mortality 9, 40-43. 
 
Bleeding may be caused by surgical factors or a disturbed hemostasis, or a combination of 
both. Examples of surgical factors are anastomosis rupture/incompetence and leakage from 
cannulation sites, which can be surgically corrected. A surgical source of bleeding is found in 
approximately 50 % of the patients undergoing re-exploration 9, 10, 44. Disturbed postoperative 
hemostasis may be related to impaired coagulation, increased fibrinolysis or platelet 
dysfunction 45-47. The cause of disturbed hemostasis is often multifactorial. It may be 
secondary to a surgical bleeding, preoperative medication or the use of CPB (Fig. 2) 48-50. A 
surgical bleeding leads to a diminished blood volume and a secondary loss of coagulation 
factors. Preoperative medication has inhibiting effects on platelet function, e.g. aspirin, 
clopidogrel, GPIIb/IIIa-blockers, and the coagulation cascade, e.g. low molecular weight 
heparin and warfarin. In general, a combination of surgical, medical and CPB-related factors 
causes the alterations in the hemostatic system (Fig. 2). 
 
 
Cardiac surgery and blood transfusions 
A large amount of patients undergoing cardiac surgery receive allogeneic blood product 
transfusion in the perioperative period. Reported average transfusion rates vary between 10-
70 % 51-53. Cardiothoracic surgery is therefore a major consumer of blood products. However, 
a minority of patients undergoing cardiac procedures (15% to 20%) consume more than 80% 
of the blood products transfused at surgery 54. 
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SURGICAL CAUSES  
 
 
POSTOPERATIVE BLEEDING 
 
 
 DISTURBED HEMOSTASIS 
 
 
 
 
 
Secondary to surgical Preoperative medication Cardiopulmonary Bypass
 
 
 
 
Fig. 2. Postoperative bleeding may be caused by surgical causes (top) or a disturbed 
hemostasis (below). A disturbed hemostasis is multifactorial, and may be caused by surgical 
factors (left), preoperative medication (middle) or the use of CPB (right). 
 
 
It is known since earlier that blood transfusion is associated with an increased risk of 
morbidity and mortality, and that it may lead to immunologic reactions and respiratory 
failure. In addition, transmission of biohazards cannot be completely ruled out 54-56. Aims to 
limit the total number of transfused blood products seem to reduce both morbidity and 
mortality 53, 57, 58. In a consensus of multiple studies, six variables stand out as important 
indicators of risk for transfusions in cardiac surgery: advanced age, preoperative anemia or 
small body size, preoperative antiplatelet or antithrombotic drugs, re-operative or complex 
procedures, emergency operations and patient comorbidities 54. 
 
Negative changes occur to blood cells when they are stored in a blood bank, and the ability of 
red blood cells to transport oxygen is diminished 59. The negative changes that underlie this 
include a reduction in cell deformability, increased vascular adhesiveness and aggregability, 
and a reduction in adenosine triphospate (ATP) and levels of 2,3-diphosphoglycerate (2,3-
DPG)59, 60. Especially the latter one is an important factor in maintaining peripheral tissue 
 
Aspirin 
LMWH 
Clopidogrel 
Warfarin 
GPIIbIIIa-blockers 
 
bleeding
Blood trauma 
 
Loss of coagulation factors 
Heparin 
Hemodilution 
Hypothermia 
Loss of coagulation factors 
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oxygen delivery capacity 59. In addition, these effects result in altered rheologic properties of 
the stored red blood cells which may negatively effect their movement in the capillaries 59.  
Since blood products used in modern medicine come from human donors, the process of 
manually assisted donation, handling, testing for infectious agents and storage of blood 
products, is associated with high costs. The number of available transfusion units in a blood 
bank may be lacking, and the sustainability is limited 61. This fact, in combination with 
transfusion related medical risks of morbidity and mortality, promotes efforts to prevent and 
by all means reduce perioperative bleeding as well as the use of blood products. A restrictive 
transfusion protocol may be beneficial not only for the patients’ outcome but also for the 
economy of the healthcare system. 
 
 
Fibrinogen 
Fibrinogen is a central protein in the human coagulation system 62. Also known as clotting 
factor I (one), it is a glycoprotein synthesized in liver cells and circulates in plasma at a 
concentration of 2.0-4.5 g/L 63, 64. In healthy human adults, about 2-5 g of fibrinogen is 
synthesized daily and the same amount is catabolized 64. The plasma half-life of fibrinogen in 
normal humans has been estimated to be 3-5 days 65. Fibrinogen is converted in plasma by 
thrombin into fibrin, which under the influence of factor XIII is formed into a meshwork at 
the site of tissue damage to minimize blood loss and stimulate tissue repair (Fig. 3) 62, 63. 
Fibrinogen is the final clotting factor activated in the coagulation cascade during hemostasis. 
In primary hemostasis it supports platelet aggregation with formation of a platelet plug, and in 
secondary hemostasis the formation of an insoluble fibrin clot 66. Fibrinogen and fibrin also 
interact with other adhesive glycoproteins, hemostatic factors and blood cells forming a 
complex system that constitutes the process of hemostasis. 
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Prothrombin Thrombin 
Fibrinogen Fibrin D-dimer 
Fig. 3. Fibrinogen is converted in blood plasma by thrombin into fibrin, forming an insoluble 
fibrin meshwork stabilized by factor XIII. Platelets interact to form a platelet plug. 
 
 
Treatment and substitution with fibrinogen 
In clinical medicine, infusion of fibrinogen concentrate has been used with increasing 
enthusiasm to treat severe surgical and trauma-related bleeding 67-69, and to substitute 
hereditary fibrinogen deficiency disorders 70-72. However, efficacy, dose-responsiveness and 
potential side effects are little studied in humans. Therapeutic fibrinogen substitution is based 
on products derived from human plasma, such as fresh-frozen plasma, cryoprecipitate or 
virally inactivated fibrinogen concentrate 73-75. Fibrinogen concentrates are manufactured 
from a pool of plasma donations 76. The risk of contamination of the donations by pathogens 
is significantly reduced by selection of donors and through screening of donations by 
serological and biochemical methods followed by a virus inactivation step including 
pasteurization 76. Recent research has focused more on purified fibrinogen concentrate than 
fibrinogen cryoprecipitate and fresh frozen plasma as a candidate to treat bleeding and correct 
dilution coagulopathy, both in animal and human experimental models. There are a number of 
recent publications in which treatment with purified fibrinogen concentrate improves 
hemostasis in experimental models of induced hemodilution and severe bleeding 77-83. 
Platelets 
Fibrin meshwork 
Platelet plug 
Factor XIII 
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Study objectives of this thesis 
Although extra-corporeal circulation has revolutionized the practice of modern cardiac 
surgery, it still has several disadvantages. It is associated with a systemic inflammatory 
response syndrome (SIRS) due to activation of cellular and humoral mediators resulting in 
complement activation and cytokine release 21, 25. SIRS initiates a potential prothrombotic 
stimulus. In addition, the production, release and circulation of microemboli and vasoactive 
and cytotoxic substances affect almost every organ and tissue within the body 25. Recognition 
of this fact has resulted in efforts to attenuate these side effects in order to reduce the risk of 
postoperative organ dysfunction and risk of bleeding complications. 
 
Studies on patients undergoing off-pump coronary artery bypass grafting surgery (OPCAB) 
have indicated that avoiding CPB reduces the postoperative systemic inflammatory response 
compared with conventional on-pump coronary artery bypass grafting (CABG) 84-87, but these 
findings have been challenged 88. Regarding clinical outcomes, OPCAB has been associated 
with less blood loss and need for transfusions, less myocardial injury, and less renal 
insufficiency compared with conventional CABG 89. On the other hand, fewer performed 
grafts and poorer graft patency has also been demonstrated 90. Compared with on-pump 
cardiac surgery, the relationship between the inflammatory response and hemostasis during 
and after off-pump cardiac surgery is less investigated. Therefore, the aim of Paper I was to 
investigate the association between selected biomarkers of inflammatory activity, hemostasis 
and bleeding after uncomplicated off-pump coronary artery bypass surgery. This was 
conducted in a prospective, descriptive study. 
 
Since bleeding is a major risk factor for increased morbidity and mortality after cardiac 
surgery, aims have been taken to in advance predict increased risk of postoperative bleeding 
in these patients 91-93. There is at present no biomarker that accurately identifies patients with 
an increased risk of bleeding. Commonly used preoperative laboratory tests such as activated 
partial thromboplastin time (APTT), prothrombin time (PT), and platelet count, have been 
demonstrated to have a low ability to predict postoperative bleeding after cardiac surgery 39, 91, 
94-96, although there are conflicting results 97-99. Clinical studies have reported an inverse 
correlation between the preoperative 100, 101 and postoperative 37, 91, 92, 102 concentration of 
fibrinogen in plasma and the volume of bleeding after cardiac surgery with CPB. Other 
studies have not found a correlation 95, 97, 103. However, it is difficult to compare studies due to 
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variations in study design, patient selection and time point for registration of bleeding. The 
type of surgery also varies, from isolated CABG 92, 100 to various CPB-related procedures 91, 
101, 102. 
 
The concept of preoperative identification of patients with an increased risk of severe 
postoperative bleeding and transfusion of blood products is interesting and offers the 
possibility to initiate countermeasures. As far as we know, no study has yet investigated if 
there is an association between the plasma concentration of fibrinogen measured the day 
before surgery and the amount of postoperative bleeding. In Paper II, we therefore designed 
a prospective descriptive study on patients undergoing isolated first-time CABG in which 
plasma fibrinogen was measured the day before surgery, and calculated the correlation to 
bleeding volume during the first 12 postoperative hours. We also investigated if the 
fibrinogen concentration and selected patient variables were predictive of blood transfusions. 
 
An increasing number of studies indicate that fibrinogen plays a more important role to 
achieve adequate hemostasis than what previously was thought in patients suffering from 
major bleeding. Until recently, guidelines have suggested a plasma fibrinogen level of >1 g/L 
to be efficient for adequate hemostasis 104-107. However, in some clinical conditions the 
critical level of fibrinogen may be higher 83. Estimates of the fibrinogen level by the Clauss-
method 108, which is the commonly used coagulation test in which plasma fibrinogen content 
is determined by the time required for clot formation to occur, may be falsely elevated in 
bleeding patients due to high levels of fibrin degradation products and the presence of colloids 
such as gelatin 109. 
 
In situations of traumatic or surgical bleeding in patients without known fibrinogen deficiency 
disorder, evidence supports a more liberal use of fibrinogen concentrate compared to what 
previously has been considered 110, 111. Also, during ongoing bleeding fibrinogen depletion 
has been described as occurring before depletion of platelets and other coagulation factors 82, 
104, 112. In recent studies, an inverse correlation between the preoperative concentration of 
fibrinogen in plasma and postoperative bleeding after CABG, even when fibrinogen levels are 
above the lower reference range, has been demonstrated 100, 101. This suggests that fibrinogen 
is a limiting factor for hemostasis after cardiac surgery. We therefore hypothesized, based on 
these studies and our own experience from paper II, that prophylactic fibrinogen concentrate 
infusion to patients undergoing CABG might reduce postoperative bleeding. Before the 
 17
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efficacy and safety of prophylactic fibrinogen infusion can be tested in larger patient 
populations, feasibility and tolerability needs to be evaluated in smaller patients groups. In 
theory, infusion of coagulation factors could potentially induce a state of hypercoagulability 
with an increased risk of thromboembolic events, such as early graft occlusion and 
myocardial infarction. In paper III, we therefore designed a prospective, randomized phase 
I-II study to assess whether prophylactic infusion of fibrinogen concentrate to CABG patients 
is feasible. Predefined secondary endpoints were effects of fibrinogen concentrate infusion on 
bleeding, transfusions, postoperative hemoglobin levels and global hemostasis. 
 
A theoretical contraindication for administration of fibrinogen concentrate is the risk of 
thromboembolism and myocardial infarction 113, 114. Studies on the clinical safety of 
fibrinogen treatment is limited, even in patients with congenital fibrinogen deficiency, but it 
has so far been reported as effective and without major adverse reactions 64, 114. A few studies 
have retrospectively evaluated the safety of fibrinogen concentrate administration to patients 
with acquired hypofibrinogenemia and on-going bleeding 68, 69, 115, and they could not 
demonstrate any adverse events related to treatment with fibrinogen infusion. In relation to 
Paper III, it was the first study ever in which fibrinogen concentrate was administered 
prophylactically to humans without hereditary or acquired fibrinogen deficiency or as 
treatment for on-going bleeding. Potential effects on other coagulation factors have so far not 
been studied. Therefore, a comprehensive test series was applied to determine the effects of 
fibrinogen concentrate infusion in patients with normal hemostasis. The aim of Paper IV, 
based on the same patient material as in paper III, was to investigate the effect of fibrinogen 
concentrate infusion on selected biomarkers of coagulation, fibrinolysis and platelet function 
in CABG patients, without known fibrinogen deficiency disorder or on-going severe bleeding. 
Aims of the study 
2. Aims of the study 
 
1. To investigate if there are associations between biomarkers of inflammatory 
 activity, hemostasis and bleeding after OPCAB (Paper I). 
 
2.  To investigate the relationship between the preoperative plasma fibrinogen 
 concentration and postoperative bleeding volume and transfusion prevalence 
 after CABG (Paper II). 
 
3.  To investigate if prophylactic fibrinogen infusion is feasible in CABG patients 
 regarding safety and tolerability (Paper III). 
 
4. To investigate if prophylactic fibrinogen concentrate infusion to CABG patients 
 reduces postoperative bleeding volume and blood transfusion requirements 
 (Paper III). 
 
5.  To investigate the effect of fibrinogen concentrate infusion in CABG patients on 
 biomarkers reflecting coagulation, fibrinolysis and platelet function (Paper 
 IV).
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3. Materials and methods 
 
Patients 
The human ethics committee at the Sahlgrenska Academy of University of Gothenburg 
approved the studies. All patients were included after written informed consent. The studies 
were performed at the Department of Cardiovascular surgery and Anesthesia at Sahlgrenska 
University Hospital, Gothenburg, Sweden. 
 
Paper I 
Ten patients undergoing OPCAB were included in the study. There were nine men and one 
woman with a mean age of 65 ± 2 years (Table 1). Exclusion criteria were unstable angina, 
redo surgery, serum creatinine >130 µmol/L, preoperative NSAID and steroid medication, 
known bleeding disorder and left ventricular ejection fraction <30% prior to surgery. 
Anticoagulant treatment with aspirin and clopidogrel was withdrawn at least one week before 
surgery. Low molecular weight heparin (LMWH) was not administered to any patient before 
surgery. 
 
 
Table 1. Patient characteristics study I. Median and range. 
Number of patients 10 
Age (years) 65 (49-77) 
Gender (M/F) 9/1 
LVEF (%) 65 (30-85) 
Number of anastomoses 1 (1-3) 
Key: F=female, LVEF= left ventricular ejection fraction, M=male 
 
 
 
Paper II 
One-hundred and seventy-five patients undergoing first-time elective CABG with CPB 
between January and June 2005 or between January and March 2006 were included in a 
prospective non-interventional observational study (Table 2). Predefined exclusion criteria 
were emergency CABG, concomitant surgical procedures, known liver or kidney disease, and 
a surgical source of bleeding at acute re-exploration. Aspirin was not discontinued before 
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surgery. LMWH was administered until the evening before surgery. Clopidogrel and warfarin 
was discontinued at least 5 days before surgery. Five patients were excluded from the study 
due to surgical source of bleeding, leaving 170 patients finally included. 
 
 
Table 2. Patient characteristics study II. Mean ± SD or number (%). 
Number of patients 170 
Age (years) 67 ± 9.4 
Gender (M/F) 128 (75) 
Unstable angina 94 (55) 
Aspirin 151 (89) 
LMWH 54 (32) 
Clopidogrel 52 (30) 
Warfarin 9 (5) 
ECC time (min) 73 ± 24 
Aortic cross clamp time 43 ± 15 
Number of anastomoses 3.0 ± 0.8 
Key: ECC=extracorporeal circulation, F=female, LMWH=low molecular weight heparin, M=male 
 
 
 
Paper III 
Twenty patients admitted for elective CABG between September and December 2006 were 
included after informed written consent. The sample size, 20 patients with complete 
evaluation randomized to two groups, was determined in agreement with the Regional 
Research Ethics Committee and the Swedish Medical Products Agency. Patients were eligible 
if they were scheduled to undergo elective CABG, and had a preoperative plasma fibrinogen 
concentration of ≤3.8 g/L. Predefined exclusion criteria were known liver or kidney disease, 
known bleeding disorder and a surgical source of bleeding at acute re-exploration. The 
patients were preoperatively risk stratified according to the EURO-score system 116. Patients 
were randomized to two groups; fibrinogen group and control group (see study design). 
Aspirin was not discontinued before surgery, while LMWH was administered until the 
evening before surgery. Clopidogrel and warfarin was discontinued at least 5 days before 
surgery. 
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Paper IV 
Study IV was performed on the same patient material as in study III. Therefore, the patient 
material, sample size and exclusion criteria are the same. 
 
Table 3. Patient characteristics study III and IV. Mean ± SD or number (%). 
 Fibrinogen group Control group 
Number of patients 10 10 
Age (years) 66 ± 9 68 ± 8 
Gender (M/F) 9/1 9/1 
BMI 28 ± 5 26 ± 4 
Smokers 0 0 
Aspirin 10 9 
Clopidogrel 1 2 
Euroscore 5.6 ± 2.1 5.6 ± 1.9 
Aortic cross clamp time 47 ± 21 44 ± 17 
ECC time (min) 73 ± 26 70 ± 24 
Number of anastomoses 2.8 ± 0.7 2.9 ± 0.9 
Key: BMI=Body Mass Index, ECC=extracorporeal circulation, F=female, M=male 
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Clinical management 
 
Surgical procedures and anesthesia 
Paper I 
Anesthesia was induced with remifentanil (0.5-1 µg/kg/min), propofol (1.5-2.5 mg/kg) and 
pancuronium (0.1 mg/kg) in all patients. The patients received 100 U heparin/kg bodyweight. 
Activated clotting time was aimed at >200 seconds. The heparin effect was not actively 
reversed after surgery. The patients were operated as reported previously 117. In short, body 
temperature was kept at minimum 36°C with the aid of elevated room temperature and a 
warming blanket. A generous crystalloid fluid regimen was kept as a means to maintain a 
sufficient filling of the heart during manipulation and grafting. To achieve a bloodless field, 
an intracoronary shunt (Flo-Thru-Shunt, Bio-vascular Inc., St. Paul, MN) was used. 
 
Paper II, III and IV 
The anesthesia in all patients was induced with 200 to 300 µg of fentanyl and 3 to 5 mg per kg 
thiopentone followed by 0.1 mg per kg pancuronium, and anesthesia was maintained with 
sevoflurane. During CPB, anesthesia was maintained with propofol. The patients received 300 
U heparin/kg bodyweight in order to maintain an activated clotting time >480 seconds. After 
completion of CPB, the heparin was reversed by the administration of protamine (1 mg 
protamine / 100 U of heparin) to an activated clotting time of less than 130 seconds. 
     The CPB circuit included a membrane oxygenator and roller pumps. Standard nonpulsatile 
CPB technique with moderate hypothermia (bladder temperature 34-35°C) and hemodilution 
was used. Cardioprotection was achieved with antegrade cold blood cardioplegia. Weaning 
off CPB was performed after rewarming to a bladder temperature of at least 36 °C. 
     In study II, all patients received 2g of tranexamic acid at anesthesia induction and at the 
end of surgery. Tranexamic acid was not used in study III and IV. Aprotinin was not used in 
any of the studies. 
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Study design and analyses 
 
Paper I 
Laboratory analysis, bleeding and calculations 
Selected biomarkers of inflammation (Il-6, Il-8, PMN-elastase, C3a, and sC5b-9) and 
hemostasis (platelet count, β-thromboglobulin, antithrombin, D-dimer and fibrinogen) were 
measured before and immediately after surgery. Preoperative samples were collected just 
prior to induction of anesthesia. Postoperative blood samples were collected at the end of 
surgery before closing the chest. Bleeding during the first 18 postoperative hours was 
registered. Correlations between markers of inflammation, hemostasis and bleeding were 
calculated. 
 
Paper II 
Laboratory analysis 
Hemoglobin concentration, platelet count, APTT and PT were analyzed the day before 
surgery. Plasma fibrinogen concentration was determined according to the method by Clauss 
108, with the use of an assay in which excess thrombin is added to diluted, low-fibrinogen-
containing plasma to determine the amount of clottable protein (STA-FIB 2, Diagnostica 
Stago, Asnieres, France). The reference value is 2.0-4.5 g per L. PT was analyzed with a 
prothrombin complex assay (Owren type, STA-R, SPA 50 Reagent, Diagnostica Stago) and 
reported as the International Normalized Ratio (INR). APTT was analyzed with a routine 
assay using APTT-reagent added to platelet poor plasma (STA-R, STA-PTT Automate 5 
reagent, Diagnostica Stago). 
 
Calculations 
The association between bleeding and transfusion and the following pre- and perioperative 
variables was investigated: age, sex, body mass index (BMI), number of grafts, unstable 
angina, extracorporeal circulation time, aortic clamp time, anticoagulation therapy, 
preoperative plasma fibrinogen concentration, hemoglobin concentration, platelet count, 
APTT, and PT. Unstable angina was defined according to the Braunwald classification 118. 
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Bleeding and transfusions 
Postoperative bleeding volume was defined as the total amount of chest tube drainage during 
the first 12 postoperative hours. In case of re-exploration, bleeding volume until re-
exploration was registered. The amount of transfused red blood cells, fresh-frozen plasma, 
and platelets during hospital stay was recorded. The responsible physicians, who prescribed 
transfusions, were not aware of the preoperative fibrinogen concentration. 
 
Paper III 
The study was a prospective randomized controlled study. Patients were randomized to 
infusion of 2g fibrinogen concentrate (Haemocomplettan®, CSL Behring, Marburg, Germany) 
or no infusion after arrival to the operating room immediately before surgery. Random 
assignment was conducted using unmarked envelopes, each containing a card indicating 
treatment with fibrinogen or control. Primary endpoint was safety with clinical adverse events 
and graft occlusion assessed by computed tomography (CT) of the heart 3–4 days after 
surgery. Clinical adverse events were defined as any clinical signs of central or peripheral 
thromboembolism, respiratory or circulatory failure, or allergic reactions during hospital stay. 
Predefined secondary endpoints were postoperative bleeding, transfusion of blood products, 
hemoglobin concentration 24 hours after surgery, and effects of fibrinogen infusion on global 
hemostasis 2 hours and 24 hours after surgery. Blood samples were collected at baseline 
(before anesthesia), 15 minutes after completed infusion, and 2 and 24 hours after completed 
surgery. 
 
Laboratory analysis 
APTT, PT, hematocrit, serum creatinine, aspartat-aminotransferase (ASAT), alanine-
aminotransferase (ALAT) and hemoglobin were measured with standard clinical methods. 
Plasma fibrinogen concentration was determined according to the method by Clauss 108. 
To assess global hemostasis, dynamic changes in clot formation was analyzed with 
thromboelastometry (ROTEM®, Pentapharm, Munich, Germany). Technical details have 
previously been described 119. ROTEM® analyses on citrated blood were performed in parallel 
on four channels (INTEM, EXTEM, FIBTEM, and HEPTEM). In each of these channels, the 
following variables were assessed: clotting time (CT), clot formation time (CFT) and 
maximum clot firmness (MCF). 
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Calculations 
Plasma concentrations of fibrinogen were adjusted to a standard hematocrit of 40% according 
to the formula: corrected concentration = measured concentration × (standard 
hematocrit/measured hematocrit) 120. 
 
Bleeding and transfusions 
Postoperative bleeding was defined as the total amount of chest tube drainage after closure of 
the sternum and during the first 12 postoperative hours. An intensive care nurse blinded to 
group assignment registered the bleeding every hour. The amount of transfused red blood 
cells, fresh frozen plasma, and platelets during the hospital stay was recorded. The responsible 
intensive care unit physicians were not informed of the preoperative fibrinogen concentration 
or group assignment. 
Computed tomography (CT) 
All CT examinations were performed with a 64-slice spiral CT scanner (GE Light Speed 
VCT, GE Medical Systems, Milwaukee, WI, USA). The protocol included an unenhanced 
scan of the chest to define the scan volume of the contrast-enhanced electrocardiogram 
(ECG)-gated study. ECG-gated tube current modulation was used and ECG-correlated image 
reconstruction was performed and sent to a workstation for further post-processing and 
evaluation of graft patency by an experienced thoracic radiologist blinded to patient group. A 
bypass graft was considered to be patent if it was filled with contrast that could be followed 
through the anastomotic site. 
 
Paper IV 
Blood samples were collected at baseline (before anesthesia), fifteen minutes after completed 
infusion, and 2 and 24 hours after surgery. Control patients did not receive any placebo 
infusion, but the second measurement is referred to as “after infusion” in both groups. The 
following biomarkers reflecting coagulation were analyzed at the four time points: fibrinogen, 
APTT, Activated Clotting Time (ACT), PT, antithrombin (AT), thrombin-antithrombin 
complex (TAT), prothrombin fragment 1&2 (PF 1&2) and modified rotational 
thromboelastometry (Rotem®). Plasma D-dimer was analyzed as a marker of fibrin 
degradation and fibrinolysis. Platelet count and platelet impedance aggregometry 
(Multiplate®) were analyzed as a measure of platelet function. 
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For APTT, PT, hematocrit, hemoglobin, fibrinogen and thromboelastometry, see above. ACT 
was measured with a Hemochron Jr Signature +® point of care device (ITC, Edison, New 
Jersey, USA). Antithrombin was measured by STA-R® using the STA®-Stachrom®AT III 
reagent (Diagnostica Stago, Asnieres, France). Reference range is 0.80 – 1.20 kIU/L. TAT 
and PF 1&2 were measured using ELISA methods with the iEMS Reader with Enzygnost* 
TAT micro reagent, reference range 1.0 – 4.1 µg/L, and Enzygnost*F1&2 (monoclonal) 
reagent, reference range 70-230 pmol/L, respectively (both Dade Behring AB, Skärholmen, 
Sweden). D-dimer was analyzed with a Latex Agglutination method by STA-R® using STA®-
Liatest®D-DI reagent, reference interval ≤0.5 mg/L (Diagnostica Stago, Asnieres, France). 
Dynamic changes in clot formation were analyzed with thromboelastometry as described in 
Paper III. Platelet impedance aggregometry was analyzed with a Multiplate® platelet function 
analyzer (Dynabyte Medical, Munich, Germany), which analyses platelet aggregability in 
whole blood after addition of different platelet receptor agonists 122. In the present study, 
adenosine diphosphate (ADP) was used as agonist with a concentration of 6.4 µmol/L. 
Increase in impedance is calculated as aggregation units x minutes (AU x min) and reported 
as area under the curve (AUC). 
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Statistics 
Paper I 
The non-parametric Wilcoxon’s paired test was used to compare pre- and postoperative 
values within the group. Correlation was analyzed with Spearman Rank Sum Test. Statistical 
significance was defined as p<0.05. All results are expressed as median and range. 
 
Paper II 
Results are expressed as mean ± standard deviation (SD) or number and percent (%). 
Statistical significance was defined as a p-value <0.05. Simple linear regression was used to 
analyze the relationship between hematologic and demographic data and the volume of 
postoperative bleeding. Multiple linear regression analysis using forward selection was then 
used to identify factors independently associated with bleeding volume. Group comparisons 
were performed with two-sample t-tests for continuous data and with chi-square tests for 
categorical data. Independent predictors for transfusion were analyzed with multiple logistic 
regression. 
 
Paper III 
Data are presented as mean ± SD. A p-value <0.05 was considered statistically significant. 
Group comparisons were made with the Student’s t-test (continuous variables) or Fisher’s 
exact test (categorical variables). Changes from baseline within a group were analyzed with 
paired t-test. For group comparisons of variables analyzed at more than one occasion, 
ANOVA for repeated measurements was used. 
 
Paper IV 
Data are presented as mean ± SD. A p-value <0.05 was considered statistically significant. 
Group comparisons of continuous variables were made with Student’s t-test. Intragroup 
changes from baseline were analyzed with paired t-test. For group comparisons of variables 
analyzed at more than one occasion, ANOVA for repeated measurements was used. 
Correlations were analyzed with Pearson’s test. 
Results 
4. Results 
“Inflammatory response and platelet activation after off-pump coronary artery bypass 
surgery” (Paper I) 
General 
All patients had an uncomplicated postoperative course and were discharged from hospital 
within 7 days. Median postoperative bleeding during the first 18 hours was 900 (190 – 940) 
ml. 
 
Inflammatory and hemostatic biomarkers 
The inflammatory biomarkers, C3a, sC5b-9, IL-6, IL-8 and PMN-elastase, did not change 
significantly during surgery compared to the preoperative levels. The hemostatic biomarkers 
antithrombin and fibrinogen levels decreased (from 0.82 IU/mL (0.75-1.05) to 0.80 (0.68-
0.97), p = 0.017 and from 2.46 g/L (1.85-3.90) to 2.36 (1.65-3.57), p = 0.012, respectively) 
and β-thromboglobulin increased significantly (from 21.7 IU/mL (11.5-62.9) to 33.9 (20.7-
115.8), p = 0.007) after surgery. D-dimer and platelet count did not differ significantly (p = 
0.51 and p = 0.11, respectively). 
 
Correlation between inflammatory response, hemostasis and bleeding 
There were significant postoperative correlations between PMN-elastase and β-
thromboglobulin (r = 0.82, p = 0.004, Fig 4), between PMN-elastase and fibrinogen (r = 0.69, 
p = 0.028) and between C3a and β-thromboglobulin (r = 0.71, p = 0.022, Fig 5). In addition, 
there were significant inverse correlations between postoperative bleeding and pre- and 
postoperative fibrinogen levels (r = -0.76, p = 0.011, Fig 6 and r = -0.84, p = 0.002, Fig 7, 
respectively), between bleeding and postoperative PMN-elastase (r = -0.75, p = 0.012, Fig 8), 
and between bleeding and β-thromboglobulin (r = -0.66, p = 0.037, Fig 9). IL-6, IL-8, C3a 
and sC5b-9 concentrations did not correlate to bleeding or PMN-elastase. 
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Figure 4 Figure 5 
Figure 6 Figure 7 
Figure 8 
Figure 9
 
Figure 4-9. Correlations between biomarkers of inflammatory response, hemostasis and 
postoperative bleeding. 
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“Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass 
grafting surgery: a prospective observational study.” (Paper II) 
 
General 
One patient with a postoperative myocardial infarction died of multiorgan failure 9 days after 
surgery. Four of the 170 patients (2.3 %) were re-explored within 12 hours due to diffuse 
postoperative bleeding. Median postoperative bleeding was 360 mL per 12 hours, range = 110 
- 2085 mL, and 29 patients (17%) were transfused with blood products. 
 
Laboratory variables 
Mean fibrinogen plasma concentration was 4.2 ± 0.9 g/L (range 2.4 – 8.1 g/L). 116 patients 
(68%) had concentrations within the normal range (2.0 – 4.5 g/L), and the remaining 54 
patients (32%) had higher concentrations. 
The mean preoperative platelet count, APTT and PT values were all within the normal range, 
except for six patients who had elevated PT (INR 1.3 – 1.9). The mean preoperative Hb 
concentration was 140 ± 14 g/L. 
 
Associations between pre- and postoperative variables, bleeding and transfusions 
There were significant inverse correlations between postoperative bleeding and preoperative 
fibrinogen concentration (r = -0.53, p < 0.001, Fig. 10), preoperative platelet count (r = -0.26, 
p < 0.001, Fig. 11), and preoperative Hb concentration (r = -0.25, p = 0.001). Neither APTT 
nor PT or preoperative anticoagulation correlated to bleeding. In multivariate testing, 
preoperative fibrinogen concentration was the only factor independently associated with 
postoperative bleeding volume (r = -0.53, p < 0.001). 
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r = - 0.53, p<0.001 
Fig 10. Correlation between 
the preoperative fibrinogen 
concentration and 
postoperative bleeding. 
. 
r= - 0.26, p<0.001 
Fig 11. Correlation between 
the preoperative platelet 
count and postoperative 
bleeding. 
 
 
Significant independent predictors of transfusion in a logistic regression model were 
preoperative fibrinogen concentration (OR 2.0, 95% confidence interval (CI) 1.1 - 3.7 per 1 
g/L decrease, p = 0.027), female sex (OR 5.0, 95% CI 1.8 - 14.7, p = 0.002), and aortic cross-
clamp time (OR 1.03, 95% CI 1.01 - 1.06 per minute, p = 0.013). The absolute risks of 
transfusion for men and women with different preoperative fibrinogen concentrations are 
displayed in the figure below (Fig 12). 
 
 
 
 
 
 
 32
Results 
 
 Risk of transfusion (%) 
80 
70 
60 
50 
40 Women
30 
20 
Men 
10 
0 
 
 
Figure 12. Absolute risk for transfusion of blood products in men and women with different 
preoperative fibrinogen plasma concentrations. 
 
  3
Preoperative fibrinogen concentration (g/L) 
2 6 4 5 7
 33
Results 
“Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A 
prospective randomized pilot study” (Paper III) 
 
General 
All patients had an uncomplicated postoperative course and were discharged from the clinic 
within 7 days. 
Fibrinogen 
Mean preoperative plasma fibrinogen concentration was 2.9 ± 0.2 g/l. Infusion of 2g 
fibrinogen concentrate increased plasma fibrinogen concentration by 0.6 ± 0.2 g/l (range 0.4 - 
1.1 g/l), while fibrinogen levels remained unchanged in the control group (p=0.002 between 
groups, Fig. 13). Plasma fibrinogen concentrations did not differ significantly between the 
groups 2 h and 24 h after surgery. 
 
 
2
3
4
5
6
7
Baseline After infusion Postop 2h Postop 24h
Fi
br
in
og
en
 c
on
ce
nt
ra
tio
n 
(g
/L
) FIB
Controls
**
 
Figure 13. Fibrinogen concentration before surgery (baseline), after infusion and 2h and 24h 
after surgery in the Fibrinogen (FIB) group and in the control group. ** = p=0.002 between 
groups. 
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Safety: adverse events and early graft occlusion 
There were no clinically detectable adverse events in the fibrinogen group. One patient in the 
control group had a perioperative myocardial infarction diagnosed with ECG and Troponin-T 
elevation. On CT-scan, there was one vein graft occlusion in the fibrinogen group and none in 
the control group. CT also detected accidentally a subclinical peripheral pulmonary embolus 
(PE) in one patient in the fibrinogen group.  
 
Bleeding, transfusions and hemoglobin levels 
Fibrinogen infusion reduced postoperative bleeding by 32% (565 ± 150 vs. 830 ± 268 ml/12h, 
p=0.010). Individual amounts of postoperative bleeding are given in Fig. 14. Blood 
hemoglobin concentration was significantly higher 24 h after surgery in the fibrinogen group 
(110 ± 12 vs. 98 ± 8 g/l, p=0.018, Fig. 15). One patient in the fibrinogen group and three 
patients in the control group received blood transfusions (p=0.29). 
 
 
Figure 14. Individual amounts of postoperative bleeding in the Fibrinogen group (left) and in 
the control group (right) (p=0.010). There was a mean reduction in postoperative bleeding 
between the groups of 32%. 
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Figure 15. Hemoglobin concentration before surgery, after infusion, and 2h and 24h after 
surgery in the Fibrinogen (FIB) group and in the control group. * = p=0.18 
 
 
Effects of fibrinogen infusion on global hemostasis after CABG 
There were no statistically significant differences between the groups in APTT or PT. Also, 
there were no significant differences in thromboelastometry values between the groups at any 
time point. 
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“Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of 
coagulation, fibrinolysis and platelet function” (Paper IV) 
 
Immediate effects of fibrinogen infusion 
Fifteen minutes after infusion, there was a slight but statistically significant decline in plasma 
levels of antithrombin in the fibrinogen group (-0.02 ± 0.02 kIU/L vs. +0.01 ± 0.03 kIU/L 
(control group), p=0.012 between the groups), while no other variables differed between the 
two groups. 
 
 
Postoperative effects of fibrinogen 
D-dimer levels were significantly elevated 2 hours after surgery in both groups (Fig. 16). 
None of the other biomarkers reflecting coagulation and platelet function differed 
significantly between the groups. 
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Figure 16. Plasma concentrations of D-dimer in the Fibrinogen group and in the control 
group. There was a significant difference 2 hours after surgery. 
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5. Discussion 
 
Cardiac surgery induces a systemic inflammatory response 22, 23, which may contribute to 
organ dysfunction and bleeding complications 22, 24. The inflammatory response is complex in 
its nature and a number of different factors may contribute 22-24. Historically, the 
inflammatory response was generally attributed to the use of CPB, but in recent years a 
number of other factors such as the operative trauma per se, regional ischemia/reperfusion 
injury and endotoxin release have been suggested to be of importance 22, 24, 123-125. There are 
indications that OPCAB reduces the postoperative systemic inflammatory response compared 
with conventional on-pump CABG 84-87, but these findings have been challenged  88. 
 
The relationship between inflammatory response, hemostasis and bleeding after cardiac 
surgery has been extensively studied but is still not fully understood 22-25, 126. There is, 
however, evidence for such an association. Rinder et al. has described adhesion of leukocytes 
to platelets during CPB 127. Inhibition of sC5b-9 decreased formation of leukocyte/platelet 
complexes and attenuated the reduction in platelet count during simulated CPB 128. Since the 
effects of surgery without CPB is less studied compared to surgery with CPB, we aimed at 
characterizing the relationship between inflammation and hemostasis after cardiac surgery by 
investigating the potential correlation between selected markers of inflammation, hemostasis 
and bleeding after OPCAB. 
 
Our results support a relationship between inflammatory and hemostatic activation after 
surgery since temporal correlations between two markers of inflammation, PMN-elastase and 
C3a, and the platelet activity marker β-thromboglobulin were demonstrated (Fig. 4 and 5). β-
thromboglobulin is a platelet specific protein which is released from granulae upon activation 
129, while circulating concentrations of PMN-elastase provides a measure of neutrophil 
granulation which may cause tissue damage 130. Three different mechanisms may explain the 
association. First, it could be a cause/effect relationship, i.e. that pro inflammatory mediators 
such as complement proteins and cytokines directly activate platelets. A second explanation 
would be that platelet-derived thrombin activates PMNs, and a final explanation would be a 
common pathway for activation of both platelets and cells releasing inflammatory mediators. 
The present study cannot discriminate between these mechanisms, but it is plausible that 
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measures primarily directed to modulate inflammatory response may also impact platelet 
activity. 
 
 
Platelet activation and inflammation vs. bleeding 
The complex effect of cardiac surgery, with subsequent inflammatory reaction on platelets, 
must not necessarily be negative with an increased risk of bleeding. On the contrary, the 
present results suggest a beneficial effect since there was an inverse correlation between β-
thromboglobulin and postoperative bleeding (Fig. 9), i.e. higher β-thromboglobulin levels 
were associated with a lower degree of bleeding. In addition, we found an inverse correlation 
between PMN-elastase and bleeding (Fig. 8), indicating that patients with a more pronounced 
postoperative inflammatory response, measured as PMN-concentration, actually bleed less 
than those with an attenuated response. This is in contrast to what has been reported 
previously. Despotis et al found evidence for an association between postoperative bleeding 
and increased inflammation 131. In this study, inflammation was defined as white blood cell 
count changes in percent. 
 
Regarding effects on clinical outcomes, previous studies have shown ambiguous results. The 
use of an antibody as a pharmacologic C5-complement suppression has been shown to reduce 
postoperative bleeding 132, 133. Approaches to optimize the biocompatibility of the CPB 
circuit, which is known to cause inflammation, has not been able to demonstrate any effect on 
bleeding 134, 135. In a recent interventional study, it was concluded that pharmacologic 
treatment by indomethacin, an immune modulator inhibiting cyklooxygenase, decreased 
complement activation consumption during CPB, but did not significantly reduce bleeding 136. 
In the same study, ketoconazole, a lipoxygenase and thromboxane A2 synthetase inhibitor, 
reduced postoperative bleeding by limiting coagulation abnormalities but did not significantly 
affect complement activation. In a few studies, steroid treatment before surgery has been 
shown to reduce levels of IL-6, Il-8 and TNF-alpha, however, without effect on clinical 
outcomes 137-140. It has been reported that corticosteroid treatment improves perioperative 
hemodynamics, but without relation to inflammatory markers 141. The results from the present 
study do not support active administration of e.g. steroid treatment to attenuate the 
inflammatory response in order to accomplish reduced postoperative bleeding. Inflammatory 
response and platelet activation may instead be beneficial in terms of hemostasis and 
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bleeding, at least up to a certain level. However, the complexity of this issue is further 
illustrated by the inverse relation between PMN-elastase and bleeding in the present study, 
while no other markers of inflammatory activation and postoperative bleeding was detected. 
 
Although still very complex, the results of paper I give further evidence for an association 
between the inflammatory response and hemostatic factors after cardiac surgery. An 
interesting finding was the strong relationship between pre– and postoperative fibrinogen 
levels and the amount of postoperative bleeding in these patients, (Fig. 6 and 7), despite the 
fact that all patients had fibrinogen levels within the normal range (2.0 – 4.5 g/L). This has by 
our knowledge not been reported before in OPCAB patients. Even though the patient material 
is limited, this suggests that preoperative fibrinogen analysis might provide information about 
risk of increased postoperative bleeding. 
 
 
Relationship between plasma fibrinogen, bleeding and transfusions 
The result that fibrinogen correlates to bleeding in paper I was followed up by a prospective, 
non-interventional, observational study in paper II. A larger patient cohort including 170 
CABG patients was studied between January and June 2005 and January and March 2006. 
The primary endpoint was to investigate if the correlation between plasma fibrinogen 
measured the day before surgery and the amount of postoperative bleeding could be 
confirmed. The reason why fibrinogen was measured the day before surgery was the 
hypothesis that low fibrinogen levels might predict risk of increased bleeding and need for 
blood transfusions. Secondary aims were to investigate possible associations between patient 
variables, bleeding and transfusions. 
 
The main finding was that preoperative plasma fibrinogen concentration was an independent 
predictor of postoperative bleeding and blood transfusions after CABG. No patient had 
fibrinogen levels below normal reference range of 2.5 g/L. As in paper I, we could confirm 
the result that the concentration of fibrinogen in plasma correlated to the amount of 
postoperative bleeding volume (r = -0.53, p <0.001, Fig. 10). The results give further evidence 
that the fibrinogen concentration, even within the normal range, is a limiting factor for 
postoperative hemostasis, and that it may be used as a biomarker to identify patients with an 
increased risk of severe bleeding and transfusions after cardiac surgery.  
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As mentioned in the introduction, some previous studies have demonstrated a correlation to 
postoperative bleeding and transfusions 37, 91, 92, 100-102, while others have not 95, 97, 103. In 
studies which demonstrated a correlation, fibrinogen was measured either preoperatively just 
before start of surgery 100, 101, or after completed surgery 37, 91, 92, 102. However, it is difficult to 
compare the studies due to variations in blood sampling, type of surgical procedures, patient 
selection and time point for registration of bleeding. 
 
To our knowledge, the present study is the first and largest so far and the only one in which 
fibrinogen is measured the day before surgery. It was designed in a prospective manner, 
exclusively to investigate the association between preoperatively measured plasma fibrinogen 
and the amount of postoperative bleeding and transfusions of blood products. We 
standardized the design by measuring fibrinogen the day before surgery instead of after arrival 
in the operating theatre. This regimen was chosen since fibrinogen concentration at time of 
surgery may be affected by preoperative fluid therapy. Another reason for this was to test the 
hypothesis that early identification of patients with an increased risk of postoperative bleeding 
may offer the possibility to initiate countermeasures.  
 
Another important question raised by this investigation is the level of plasma fibrinogen 
required to maintain optimal hemostasis in the perioperative period. It has for a long time 
been considered that a laboratory plasma level of >1 g/L is sufficient for appropriate 
hemostasis 111. In accordance, most transfusion algorithms in general surgery and trauma do 
not treat low fibrinogen levels unless they are <1 – 1.5 g/L, which is below the normal values 
of 2 – 4.5 g/L 106, 142. However, the present results indicate that this level may not be sufficient 
when the hemostatic system is challenged by cardiac surgery and the use of CPB. The results 
suggest that plasma fibrinogen concentration is a limiting factor for postoperative hemostasis, 
and that fibrinogen levels in the lower normal range may be too low to ensure an appropriate 
coagulation during and after major surgical procedures. Our results are supported by two 
recent studies. In patients suffering from post partum bleeding, fibrinogen levels <2 g/L was 
100 % predictive of severe postpartum hemorrhage, and a fibrinogen plasma concentration of 
4 g/L was suggested to be the lowest transfusion trigger level, in order to maintain adequate 
hemostasis 110. An in-vitro dilution model simulating coagulopathy after acute loss of two 
blood volumes demonstrated that clot formation is optimized only after increasing fibrinogen 
concentration to above 2 g/L 83. 
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In the present study, patients with a plasma concentration of approximately >5 g/L generally 
bled less compared with patients with lower values (Fig. 10). The relationship is not straight 
linear, but supports previous studies about the importance of an adequate fibrinogen 
concentration in relation to bleeding tendency 83, 110. In addition, the risk of being transfused 
varied in relation to the preoperative plasma fibrinogen level (Fig. 12). Altogether, the results 
give further evidence that the plasma fibrinogen concentration is a limiting factor for 
postoperative hemostasis and that fibrinogen levels in the lower normal range may be too low 
to ensure an appropriate coagulation during and after major surgical procedures. 
 
There are several potential reasons why fibrinogen levels were associated with bleeding in the 
present study. Fibrinogen supplementation in animal experiments and in-vitro studies has 
been shown to counteract dilutional coagulopathy, impaired hemostasis caused by platelet 
deficiency, and to improve laboratory clot formation tests measured by ROTEM® 
thromboelastometry 77-80, 83, 113, 143-145. Therefore, it is possible that the relationship between 
fibrinogen and bleeding is mediated by such effects, since hemodilution and platelet 
consumption have been suggested to be two important factors in the pathogenesis of severe 
bleeding after cardiac surgery 35, 48, 146. 
 
There was also a significant inverse correlation between platelet count and bleeding, but this 
correlation was less pronounced (r = -0.26, p <0.001, Fig. 11). PT and APTT did not correlate 
to bleeding. In multivariate testing, fibrinogen was the only independent predictor among 
these coagulation biomarkers. We therefore speculate that measurement of the preoperative 
fibrinogen level provides more information about potential bleeding risk, than the standard 
coagulation screening tests used today. 
 
Sex is a well known risk factor for transfusion 146, 147, which was confirmed in the present 
study. However, women did not bleed more compared with men. One explanation may be 
lower basal hemoglobin levels and a smaller total blood volume in women, resulting in a 
more pronounced hemodilution during and after CPB, with subsequently more women 
reaching the transfusion trigger. The association between preoperative fibrinogen 
concentration and absolute risk of transfusion is given in Fig. 12. The absolute risk of 
transfusion was moderate in the study group of elective CABG patients, with only 17 percent 
of the patients receiving any transfusion. However, Fig. 12 shows that the risk of transfusion 
varies considerably between patients. In a woman with a preoperative fibrinogen 
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concentration of 3.0 g/L, the risk is markedly higher than for a man with a fibrinogen 
concentration of 5.0 g/L (58% vs. 6%). 
 
 
Effects of fibrinogen infusion on postoperative bleeding and transfusions 
Based on the results in paper II, which demonstrated a strong inverse correlation between the 
preoperative concentration of fibrinogen in plasma and the amount of postoperative bleeding 
after CABG surgery, we hypothesized that prophylactic fibrinogen concentrate infusion 
before CABG could reduce postoperative bleeding. However, infusion of coagulation factors 
before or during a surgical procedure may, at least in theory, induce a state of 
hypercoagulability with increased risk of thromboembolic events, such as early graft 
occlusion and myocardial infarction. To investigate this, a prospective, randomized phase I-II 
pilot study was designed. Primary endpoint was clinically detectable adverse effects and graft 
occlusion assessed by multi-slice computed tomography. Secondary endpoints were effects of 
fibrinogen concentrate infusion on bleeding, transfusions, postoperative hemoglobin levels 
and global hemostasis. This study was a clinical attempt to investigate the feasibility of 
prophylactic fibrinogen infusion in patients undergoing cardiac surgery with CPB, and with 
normal plasma coagulation. None of the patients suffered from any preoperative fibrinogen 
deficiency. 
 
The results show that prophylactic fibrinogen infusion reduced postoperative bleeding by 
approximately 30 % (Fig. 14), and maintained postoperative hemoglobin at a higher level in 
patients who were randomized to fibrinogen infusion compared with the control group (Fig. 
15). There were also less transfused patients in the fibrinogen group, n 1/10, compared with 
controls, n 3/10, but the difference was not statistically significant.  
 
We could not detect any clinical adverse effects that could be directly related to the fibrinogen 
infusion. Computer tomography discovered coincidentally one subclinical small peripheral PE 
in one of the patients in the fibrinogen group. However, this finding is not necessarily related 
to the fibrinogen infusion since the reported prevalence of clinically detectable PE in patients 
undergoing CABG with CPB is 0.4 - 9.5 % (mean 3.4 %), while the prevalence of subclinical 
PE, i.e. when the patient is asymptomatic, is not known 148-150. However, in patients 
undergoing OPCAB, the prevalence of subclinical PE was recently reported to be as high as 
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25 % 151. The prevalence of subclinical PE in the present study, 10 % in the fibrinogen group, 
is therefore probably what could be expected in the current study population. There was also 
one early vein graft occlusion in the fibrinogen group, resulting in an occlusion rate of 3.7 % 
in this group. The prevalence of early graft occlusion after CABG has previously been 
reported to be 3.9 % after five days 152, and 12 % in early follow up (mean 0.9 month) after 
surgery 153 . Therefore, there is no certain evidence of an increased occlusion rate in the 
present study, not overall nor in the fibrinogen group. 
 
The significant reduction in bleeding volume further supports the hypothesis from paper II 
that plasma fibrinogen concentration is a limiting factor for postoperative hemostasis, and that 
fibrinogen levels in the lower normal range may be too low to ensure an appropriate 
coagulation during and after cardiac surgery. As mentioned previously, this finding is 
supported by recent clinical 68, 73, 110, 154, 155 and laboratory studies 78-81, 83, 143, 144. Despite this, 
the mechanism behind reduced bleeding, and the relationship between fibrinogen and 
bleeding is not clarified. Plasma fibrinogen was no longer different between the groups two 
hours after surgery. This may be interpreted as stimulated fibrin generation leading to an 
improved hemostasis. Fibrinogen also interacts with platelets by binding to GPIIb/IIIa 
receptors leading to a stabilized fibrin network, rapidly forming an active seal at the site of 
vascular damage (Fig. 3) 156. This mechanism may also have contributed to improved 
hemostasis and reduced bleeding. 
 
There is a few but increasing number of prospective studies on humans. Rahe-Meyer et al 
investigated patients operated for aortic valve replacement or aortic aneurysm. Fibrinogen 
was given prophylactically following a blood transfusion algorithm, which resulted in reduced 
transfusion requirements and postoperative bleeding compared with patients treated primarily 
with blood products alone 157. Similar results and study design was seen in patients operated 
for thoracoabdominal aneurysms 158. Fibrinogen has also been shown to improve clot 
formation in patients with dilutional coagulopathy during orthopedic surgery 154, and in 
children undergoing craniosynostosis surgery 73. When it comes to retrospective studies, 
administration of fibrinogen concentrate has been shown to significantly reduce bleeding and 
blood transfusions in patients with low to normal fibrinogen levels treated for massive 
hemorrhage related to trauma, surgery and obstetric complications 68. Similar results were 
demonstrated by Weinkove et al 115.  
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One important objective in this study was safety since artificially stimulated coagulation, at 
least theoretically, may lead to an increased risk of harmful hypercoagulability. In addition to 
assessing clinical symptoms and graft patency, we were interested in the effects of fibrinogen 
concentrate infusion on global hemostasis assessed by thromboelastometry. There was 
moderately impaired global hemostasis in both groups 2 hours after surgery, but no significant 
differences were found between the groups. As mentioned earlier, fibrinogen infusion 
statistically increased plasma fibrinogen by 0.6 ± 0.2 g/L. The reason why this was not seen 
on thromboelastometry variables, FIBTEM in particular, may be several. One possible 
explanation is that the increase of fibrinogen by 0.6 g/L was too discrete or that the FIBTEM 
test was not sensitive enough. Another possible explanation may be that the difference was 
concealed, since thromboelastometry measurements were not performed intra-operatively 
when the difference in plasma fibrinogen concentration was likely still significant between the 
groups. 
 
The global hemostasis had almost normalized 24 h after the operation. The lack of changes in 
thromboelastometry variables between the two groups may not necessarily be interpreted as 
lack of effect of the fibrinogen infusion. Instead, the absence of unwanted hypercoagulability 
was concomitant with desired clinical effects. However, the study is underpowered to make 
any robust conclusions about safety and efficacy, and the current results are not sufficient to 
propose that prophylactic fibrinogen infusion should currently be used to prevent bleeding in 
any cohort of CABG patients. 
 
 
Effects of fibrinogen on coagulation, fibrinolysis and platelet function 
The major finding in paper III was that prophylactic treatment with fibrinogen concentrate 
was feasible and significantly decreased postoperative blood loss after CABG. Postoperative 
hemoglobin was maintained at a higher level, without evidence of an increased incidence of 
thrombo-embolic events, such as graft occlusion, myocardial infarction and PE. As mentioned 
previously, this was the first time fibrinogen concentrate was administered to patients without 
fibrinogen deficiency or on-going severe bleeding, and therefore, we found it essential from a 
safety point-of-view to thoroughly monitor the effect of fibrinogen concentrate on markers of 
coagulation, fibrinolysis and platelet function. 
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In addition to conventional markers of hemostasis and fibrinolysis, we used impedance 
aggregometry (Multiplate®) to assess platelet function and rotational whole blood 
thromboelastometry (ROTEM®) to analyze global hemostasis. As primary aim, we were 
interested in investigating immediate effects of fibrinogen measured 15 minutes after 
completed infusion, before the on-start of surgery. As secondary aim, we studied 
postoperative effects measured 2 and 24 hours after completed surgery. 
 
Regarding the primary aim, fibrinogen concentrate infusion induced no or minimal changes in 
biomarkers of coagulation, fibrinolysis and platelet function. Antithrombin, an anti-coagulant 
factor in human blood plasma which is usually decreased during and after cardiopulmonary 
bypass 159, was marginally but significantly decreased in the fibrinogen group compared with 
the control group. However, both measurements were made before heparinazation and the 
biological meaning of this variation is likely irrelevant. TAT and PF 1&2, molecular markers 
of thrombin activity and generation 159, 160, were discretely elevated in both groups, somewhat 
more markedly among controls, but there was no significant difference between the groups. 
Discrete variations in TAT and PF 1&2 might be due to sampling technique and the analysis 
itself rather than increased thrombin generation 160. Since the differences were minor, this 
cannot be ruled out. Also, no major surgical trauma had yet occurred that would stimulate 
thrombin generation to a larger extent. 
 
Our second aim was to compare the fibrinogen group and the control group in relation to 
completed surgery. In this analysis, we used measurements after infusion as baseline and 
compared this to measurements 2 and 24 hours after surgery. The elevation in plasma 
fibrinogen after infusion was no longer significantly different between the groups 2 and 24 
hours after surgery. Plasma concentrations of D-dimer were, as expected 161, increased after 
surgery compared with the preoperative levels (Fig. 16). Furthermore, D-dimer was 
significantly higher in the fibrinogen group 2 hours after surgery compared with the control 
group (p = 0.03, Fig 16). The results indirectly indicate an increased fibrin generation in the 
fibrinogen group during the preceding period of time, i. e. during surgery, which may be 
partly responsible for the reduced postoperative blood loss in this group. Also, the fact that no 
or minimal changes in biomarkers were seen in the present study may indicate that infusion of 
fibrinogen, even in a low dose of 2g, has a clinical effect without unwanted signs of harmful 
hypercoagulability. 
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Clinical implications 
The fact that the plasma fibrinogen concentration measured the day before surgery correlates 
to postoperative bleeding is very interesting in a clinical point of view. Fibrinogen is often 
considered merely an acute phase reactant or a marker for risk of thrombo-embolism or 
cardiovascular disease, rather than a potential pro-hemostatic factor 111, 162. Since fibrinogen is 
the most abundant protein in the hemostatic system, (>2.5 g/L, compared with 145 mg/L for 
all other coagulation factors together 111), the overall hemostatic capacity was thought not to 
depend on minor changes in the plasma concentration of fibrinogen 111. An increasing number 
of studies suggest that the plasma fibrinogen concentration is probably more important for 
maintaining sufficient hemostasis caused by hemodilution and/or bleeding than previously 
recognized, especially since fibrinogen seems to be the coagulation factor which first reaches 
critically low plasma levels 68, 104. Our results further support the importance of adequate 
plasma fibrinogen levels, since patients with higher levels in general bleed less. Measuring 
the plasma concentration the day before surgery offers the possibility to initiate 
countermeasures. This was investigated in paper III, which showed reduced bleeding and less 
transfusions among patients who received fibrinogen prophylactically. However, larger and 
placebo controlled studies are warranted to investigate this closer. It is noteworthy that there 
was a significant difference in bleeding volume between the groups, despite the fact that there 
were only 10 patients in each group. 
 
One may speculate if it is worth the effort of reducing transfusions of blood products by the 
prophylactic administration of another human derived plasma product such as fibrinogen. 
However, virally inactivated fibrinogen concentrate seems to be associated with less negative 
side effects compared with red blood cells, plasma, platelets and cryoprecipitate 68, 69, 113. 
Accumulating evidence suggest that transfusion of allogeneic blood products, such as red 
blood cells, fresh frozen plasma, platelets and cryoprecipitate, are associated with increased 
risk of morbidity and mortality 54-56, 163, 164. Management of traumatic and perioperative 
bleeding with plasma derived or recombinant coagulation factor concentrate, such as 
fibrinogen and FVII, may therefore reduce transfusion of allogeneic blood products. It may 
also be beneficial to use fibrinogen early in the perioperative period since this has been shown 
to significantly reduce bleeding and the need for allogeneic blood transfusions 157. 
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Limitations 
There are limitations in these studies that should be mentioned. In paper I, the inflammatory 
variables were not altered significantly by the surgical procedure. The study design does not 
allow any conclusions about the magnitude of the inflammatory response after OPCAB 
surgery since the single postoperative measurement was performed immediately after surgery, 
and some of the investigated inflammatory mediators have a markedly later peak 
concentration 135. Furthermore, the investigation was performed in low risk patients and only 
a few markers of inflammation and hemostasis were analyzed. Both the inflammatory 
response and hemostasis after cardiac surgery are extremely complex processes, and other 
markers and mediators may react differently. In addition, the limited number of patients 
included infers a risk of a statistical type II error. 
 
Paper II does not prove causality, even if the results suggest that fibrinogen per se is a limiting 
factor for postoperative hemostasis. The results may be caused by other factors that vary in 
correlation with fibrinogen. This study is a single-center experience. Transfusion thresholds, 
hematologic practice, use of thromboelastometry, discontinuation of anticoagulants, and the 
use of perioperative antifibrinolytics may not reflect worldwide practice, and the 
generalizability of our results needs thus to be proven in larger multicenter studies. 
 
In paper III, it should be noted that this is a pilot study focusing on feasibility and tolerability 
of fibrinogen prophylaxis. The study is underpowered to make any robust conclusions about 
safety and efficacy and the current results are thus not sufficient to propose that prophylactic 
fibrinogen infusion currently should be used to prevent bleeding in any cohort of CABG 
patients. It should also be noted that the preoperative fibrinogen level alone is insufficient to 
determine whether a patient is at high risk for bleeding complications after cardiac surgery. 
Other factors such as patient characteristics, preoperative medication, the magnitude of the 
operative trauma and preoperative hemoglobin and platelet levels may be equally or more 
important. Other limitations include the absence of placebo-treatment in the control group and 
that factor XIII activity was not analyzed before surgery. 
 
Paper IV has the same main limitation as paper III, with a low number of study participants, 
n=20. A statistical type II error can therefore not be ruled out. It is possible that changes in 
hemostatic factors would have been detected in a larger number of patients. The study size 
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was limited as a safety precaution since this was the first study on the subject, and the 
authorities restricted the allowed number of participants. Another limitation may be the 
number and choice of biomarkers, where other biomarkers may have yielded a different 
result. However, the current markers are common in clinical practice. Furthermore, the 
biomarkers were not analyzed during surgery. Since there was a difference in postoperative 
bleeding between the groups, one may speculate that there may be differences in the 
hemostatic variables during surgery, which were not detected by the pre- and postoperative 
measurements. It is also possible that a higher dose of fibrinogen in paper III would have 
generated detectable differences by thromboelastometry. The used dose of 2g, corresponding 
to 18-34 mg/kg bodyweight, is rather small. In patients with congenital afibrinogenemia, a 
recommended starting dose of 70 mg/kg bodyweight raised the plasma fibrinogen level by 1 
g/L, which may be easier to detect with thromboelastometry 64. 
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6. Summary 
 
1. There are associations between the inflammatory response, hemostasis and 
 bleeding after OPCAB (Paper I). 
 
2. The preoperative fibrinogen plasma concentration correlates independently to 
 bleeding volume and transfusion prevalence after CABG (Paper II). 
 
3. Prophylactic fibrinogen concentrate infusion in CABG patients seems feasible 
 without clinically detectable side effects (Paper III). 
 
4. Prophylactic fibrinogen concentrate infusion in CABG patients significantly 
 reduces postoperative bleeding (Paper III). 
 
5. Prophylactic fibrinogen concentrate infusion in CABG patients results in no or 
 minimal changes in biomarkers reflecting coagulation, fibrinolysis and platelet 
 function (Paper IV). 
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 Sammanfattning på svenska 
Blödning i samband med hjärtkirurgi 
 
Hjärtkirurgi med användning av hjärtlungmaskin innebär att det aktuella ingreppet utförs på 
stillastående hjärta, vilket är vanligt vid operationer på kranskärl, hjärtklaffar och vid hjärt- 
och lungtransplantationer. Ingreppet medför dessvärre en kraftig inflammatorisk aktivering i 
blodet och en stor risk för blödningskomplikationer, som kan uppstå under och efter 
operationen. Kranskärlsoperationer kan även utföras utan hjärtlungmaskin på slående hjärta, 
men är inte lika vanligt förekommande. 
 
Studiernas mål 
I det första delarbetet görs en beskrivande studie över sambandet mellan inflammatoriska 
ämnen i blodet, koagulationsmarkörer och mängden blödning hos patienter som 
kranskärlsopereras utan hjärtlungmaskin. I delarbete II studeras sambandet mellan 
plasmakoncentrationen av fibrinogen och mängden postoperativ blödning samt behov av 
blodtransfusioner. Syftet är att kartlägga fibrinogenets eventuella möjlighet att prediktera risk 
för blödning och blodtransfusioner. I delarbete III studeras huruvida förebyggande behandling 
med fibrinogenkoncentrat innan kranskärlskirurgi är säkert att genomföra, samt om 
blödningsmängd och transfusionsbehov reduceras av behandlingen. Hypotesen är att 
substitution med fibrinogen är gynnsamt till hjärtopererade patienter. I delarbete IV kartläggs 
effekterna av fibrinogenbehandling på utvalda markörer för koagulation, fibrinolys och 
trombocytfunktion. 
 
Material och metoder 
I delarbete I studerades 10 elektiva patienter som genomgick kranskärlskirurgi utan 
hjärtlungmaskin (OPCAB). Utvalda markörer för inflammation och hemostas mättes före och 
efter kirurgi. I delarbete II studerades 170 elektiva patienter som genomgick kranskärlskirurgi 
med användning av hjärtlungmaskin. Plasmakoncentrationen av fibrinogen mättes dagen 
innan kirurgi. Postoperativ blödning och antalet blodtransfusioner registrerades. I delarbete III 
studerades 20 elektiva kranskärlspatienter som randomiserades till 2 grupper där 10 patienter 
fick behandling med 2g fibrinogenkoncentrat innan kirurgi, och den andra gruppen fick 
ingenting. Blödning och blodtransfusioner samt förekomst av graftocklusion studerades. I 
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delarbete IV studerades samma patientmaterial med avseende på effekter av 
fibrinogenbehandling på markörer för koagulation, fibrinolys och trombocytfunktion. 
 
Resultat 
I delarbete I fann vi signifikanta korrelationer mellan bland annat inflammationsmarkörerna 
PMN-elastase och C3a, och hemostasmarkören β-thromboglobulin. Ett omvänt samband 
mellan plasmakoncentrationerna av pre- och postoperativt fibrinogen, postoperativt β-
thromboglobulin och postoperativt PMN-elastase, och mängden postoperativ blödning 
förelåg. I delarbete II fann vi ett signifikant, inverst samband (r=-0.53, p<0.001) mellan 
plasmakoncentrationen av fibrinogen och mängden postoperativ blödning.  Fibrinogen var 
enda oberoende prediktor för postoperativ blödning. Fibrinogen, kvinnligt kön och 
aortaklamp-tid var oberoende prediktorer för att bli blodtransfunderad. I delarbete III fann vi 
inga kliniskt detekterbara biverkningar. Postoperativ blödning reducerades med 32 %. I 
delarbete IV fann vi inga större skillnader i markörer för koagulation, fibrinolys och 
trombocytfunktion mellan grupperna, varken direkt efter fibrinogeninfusion eller efter 
avslutad kirurgi. En förhöjd nivå av D-dimer påvisades i fibrinogengruppen jämfört med 
kontroller.  
 
Slutsatser 
Det finns evidens för ett samband mellan inflammatorisk aktivering och hemostas efter 
hjärtkirurgi. Inflammation samt aktiverade trombocyter förefaller i detta sammanhang inte 
vara av ondo, utan kan bidra till minskad postoperativ blödning. Plasmakoncentrationen av 
fibrinogen är en begränsande faktor för postoperativ hemostas och dess preoperativa nivå 
förefaller kunna prediktera risk för blödning och blodtransfusioner efter hjärtkirurgi. 
Förebyggande behandling med fibrinogenkoncentrat minskar den postoperativa 
blödningsvolymen signifikant efter kranskärlskirurgi, utan tecken på postoperativ 
hyperkoagulabilitet eller kliniskt detekterbara biverkningar. Effekterna av fibrinogen på 
markörer för koagulation, fibrinolys och trombocytfunktion är marginella. 
 
